Valeant Pharmaceuticals International, Inc. (NYSE:VRX)
The Company fell -0.54% and finished at $22.24. The daily volume was measured at 12.35 million shares. The 52-week high of the share price is $253.62 and the 52-week low is $18.55. The company has a market cap of $7.88 billion. Its latest closing price has a distance of -3.03% from SMA20 and is -5.59 down than SMA50. The stock currently has Price to Sales (P/S) value of 0.74 where Price to Book (P/B) value stands at 1.36.VRX is currently showing ROA (Return on Assets) value of -1.5% where ROE (Return on Equity) is -12.1%.
Return on equity (ROE) measures the rate of return on the ownership interest (shareholders’ equity) of the common stock owners. It measures a firm’s efficiency at generating profits from every unit of shareholders’ equity (also known as net assets or assets minus liabilities).
VRX is currently showing 354.18 million shares outstanding as compared with the 332.75 million total shares float.
The Stock has its Beta Value of 0.29 and ATR (Average True Range) of 1.2. The Weekly and Monthly Volatility of the stock are 5.03% and 4.98% respectively. The weekly performance of the company stands at -3.85 percent while it’s 1-month and 3-month returns are -3.56 percent and -35.52 percent.
By looking at Valeant Pharmaceuticals International, Inc. (VRX) YTD (year to date) performance, the stock shows Negative value of -78.12%. If the YTD value is Negative, it means that the stock is trading poorly. If the YTD value is Positive, this means the stock is appreciating.
The High price target of the company’s Share is at $175 based on the calculations and analysis of 18 brokers. According to the analysts, the company has the Low Price target of $11 whereas, the Mean Target is estimated by the brokers is $42.61.
For an overview on Recommendation Trends, 3 Analysts assigned the stock as Strong Buy. 1 said it’s a Buy, 11 assigned Hold rating where 4 stated the stock as Underperform and 1 marked the stock as Sell.
While Looking at the Earnings Estimates of the company, The Average Earnings Estimate for the Current Fiscal quarter is measured as $1.48 by 17 analysts. They are also projecting the Low EPS estimate as $1.2 as compared to the Higher EPS estimate of $1.77.
Now when we talk about Revenue Estimate for the current Fiscal Quarter, Average Revenue Estimate of Valeant Pharmaceuticals International, Inc. (VRX) is projected as $2.46 Billion where Low Revenue estimate and High Revenue Estimates are $2.3 Billion and $2.6 Billion respectively by 13 analysts.